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In August 2014, the Ministry of Health (the Ministry) held a workshop to 
discuss strategies for achieving increased coverage of Human 
Papillomavirus (HPV) immunisation in the future. 
 
This document outlines a plan for progressing and revitalising the HPV 
Immunisation Programme (the Programme) for 12-year-old girls. The plan 
uses the underlying principles of the Ministry’s modified four-point action 
plan, Plan, Engage, Promote and Monitor, and the World Health 
Organization (WHO)’s1 Global Vaccine Action Plan (GVAP). 
 
The Ministry has adopted these plans and applied these models in order to achieve the new HPV 
immunisation coverage target of 75 percent for all 12-year-old girls by December 2017. 
 
Background  
HPV is responsible for a substantial burden of disease in New Zealand women, most 
importantly in terms of cervical cancer. The virus is highly transmissible and affects the majority 
of women and men at some stage in their lives. In most cases, the infection will clear 
spontaneously after some time. However, for a small number of people, persistent HPV 
infection progresses to changes in the cells and subsequently develops into cervical cancer or 
cancers of the throat, neck and anogenital region. 
 
In September 2008, the Ministry launched a three-dose HPV immunisation programme for 
12-year-old girls as part of the funded National Immunisation Schedule (the Schedule). 
 
The Programme aspires to achieve herd immunity2 against HPV at a level that reduces the 
spread of the HPV infections that lead to cervical and other cancers. 
 
Māori and Pacific women have a higher incidence of HPV-related cancers compared to New 
Zealand European women. From its outset, the Programme has prioritised Māori and Pacific 
coverage. 
 
Since 2010, when rates of coverage could be measured, approximately 55 percent of girls in the 
eligible age ranges have been immunised. For herd immunity, coverage needs to be 
approximately 75–80 percent. The national coverage target for all other primary childhood 
immunisations listed on the Schedule is 95 percent. The Ministry considers this Programme 
should achieve similar rates of coverage. 
1 The World Health Organization is a specialised agency of the United Nations that is concerned with international 
public health. 
2 Herd immunity refers to a level of immunity within the population that is sufficient to protect both immunised 
and unimmunised people. 
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 Implementation to date 
Initiation of the Programme 
Internationally, HPV immunisation programmes are most commonly offered through school-
based immunisation programmes (SBIPs). Since 2009, the Ministry has administered the 
Programme primarily to girls in school Year 8; public health nurses (PHNs) deliver it in schools. 
Alternatively, general practitioners (GPs), practice nurses, youth health or other health clinics 
(such as family planning clinics) offer the vaccine. 
 
When the HPV SBIP was established, the Ministry implemented a ‘catch-up’ programme for a 
wider age range of girls, offering those in school Years 9–13 immunisation through schools or 
health providers. In December 2010, the school-delivery component of the catch-up programme 
ceased. 
 
In Canterbury, the HPV vaccine was previously provided primarily through general practice, 
with a catch-up school programme in Year 10. Following a recommendation from PHARMAC’s3 
Pharmacology and Therapeutics Advisory Committee (PTAC) Immunisation Subcommittee in 
February 2015, Canterbury DHB will offer HPV immunisation through the SBIP in Year 8 
beginning in 2016. 
 
Coverage targets and achievement to date 
The initial coverage target was 90 percent for dose three for all 12-year-old girls by 31 December 
of the year in which the girl became eligible. However, DHBs considered the target to be 
unachievable (because, in most areas, the SBIP was new), and the Ministry revised the targets. 
 
Up until December 2014, the revised targets for 12-year-old girls were: 
• Dose one – 70 percent 
• Dose two – 65 percent 
• Dose three – 60 percent.4 
 
(See also Appendix B, which shows the DHB end-of-year cohorts for 2001.) 
 
Figure 1 on the following page shows national HPV immunisation dose three coverage from 2011 
to 2013 (ie, for birth cohorts 1998–2001). During this period, coverage for Pacific peoples and 
Asians exceeded the 60 percent target; coverage for other ethnicities and the total population 
remained below it. 
 
The New Zealand Programme did not achieve the same success in reaching high coverage like 
Australia and the United Kingdom and, of concern for Programme leads, Figure 1 highlights that 
Māori and Pacific coverage had started to decrease. 
3 PHARMAC is the New Zealand Crown agency that decides, on behalf of DHBs, which medicines (including 
vaccines) and related products to subsidise for use in the community and public hospitals. 
4 From 1 January 2015, DHBs are aiming at a 65 percent fully immunised dose three target. 




Figure 1: HPV immunisation dose three coverage by ethnicity, vaccination and eligible 
birth cohort, 1 January 2010–31 December 2014 
 
Note: The data will be expanded during 2015 to include figures for New Zealand 
European, and a breakdown by deprivation area. 
Source: Data Mart, 13 January 2015 
 
The Ministry needs to revitalise its Programme in order to increase coverage to at least a rate 
that would provide herd immunity. A national workshop was agreed. 
 
The workshop 
The 2014 HPV workshop was held for DHB funding and planning managers who oversee 
immunisation services, PHNs, primary health organisations (PHOs), the Immunisation 
Advisory Centre (IMAC) and HPV immunisation programme managers. These workshop 
participants considered the cost-effectiveness of the Programme at current coverage levels, 
international approaches to HPV immunisation programmes and the questions listed below. 
a) How do we de-stigmatise/normalise the Programme? 
b) Should we transition the Programme to Year 7 in schools, and if so, how? 
c) What are the key requirements to transitioning from a three-dose HPV schedule to a 
two-dose schedule? 
d) Should the current 60 percent three-dose HPV target be incrementally increased to reach 
the recommended 75 percent coverage? 
 
Possible solutions were suggested on how coverage could improve (see Figure 2). 
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 Figure 2: Possible solutions to improve coverage discussed at the workshop 
 
 
There was agreement by the workshop participants that one of the keys to increasing the HPV 
coverage was to incrementally increase the dose three coverage target to achieve 75 percent by 
31 December 2017. DHBs and IMAC, who provided feedback, also support this change. 
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Increasing HPV coverage: 
discussion 
This section sets out some of the discussion points noted above in Figure 2 for achieving 
increased HPV immunisation coverage in the future, using the WHO’s GVAP objectives as a 
framework. 
 
The WHO GVAP objectives 
As a platform for all the Ministry’s immunisation programmes, the Ministry’s Immunisation 
Team has adapted the six core objectives of WHO’s GVAP: ownership, shared responsibility and 
partnership, equity, integration, sustainability and innovation (see Appendix A, which sets out 
how these objectives have been adapted for New Zealand in a broader sense). 
 
The Ministry recommends applying these objectives to the current Programme, as follows. 
 
Table 1: Application of the GVAP principles to the Programme 
Objective Description 
Ownership All providers and the wider health sector recognise the importance of the Programme and 
work collectively to achieve agreed targets. 
Shared responsibility 
and partnership 
The Ministry, the National Screening Unit (NSU) and DHBs, as partners and customers, 
respect the role of primary health care providers and the community itself in increasing 
coverage, and actively look for opportunities to improve the Programme. 
Equity The Programme deliverables are fair and just; in particular for vulnerable populations 
such as Māori, Pacific peoples and low-income groups. 
Integration The Programme is integrated with other programmes on the Schedule in order to achieve 
better outcomes for young women and improve the efficiency of SBIP delivery. 
Sustainability The Programme continues to receive funding and remains a government priority. 
Innovation The Programme undergoes continuous improvement, with an aim to increase coverage 
rates and quality. 
 
Using the modified WHO GVAP, the Ministry’s Immunisation Team continues to work with the 
NSU and DHBs to improve the HPV immunisation coverage. 
 
A more detailed exploration of the six objectives follows. 
 
Ownership 
‘Ownership’ of immunisation programmes occurs at multiple levels. The Minister continues to 
support the delivery of the Schedule. In 2010, the Health Select Committee inquiry into how to 
improve completion rates of childhood immunisation considered that immunisation is a highly 
effective strategy for preventing infectious diseases throughout life. The Government, through a 
number of recommendations, supports timely immunisation. 
 
In alignment with the recommendations of the 2010 Health Select Inquiry, many DHBs 
demonstrate ownership by providing resources for the delivery of SBIPs. 
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 Currently there is an opportunity to expand ownership of the Programme to PHOs and general 
practices. This would be a way to actively involve families in the effort to ensure that girls aged 
14 years complete their HPV immunisation. PHNs and general practice teams could work 
together to develop initiatives to engage with families to this end. 
 
Shared responsibility and partnership 
Up until 2014, there was a disconnection between the SBIP and general practice delivery of the 
HPV vaccine. The Programme is delivered mainly through the SBIP, but general practices were 
not well equipped to specifically offer the vaccine to those who declined it at school. 
 
To date, general practice teams have not been given clear guidelines about the optimal time for 
recalling girls who have not received the vaccination at school. Moreover, anecdotal evidence 
suggests that many practices do not routinely stock the HPV vaccine. Although the SBIP notifies 
individual girls’ vaccine records to their GPs, in reality these records are frequently inadequate 
or incomplete. 
 
There is an opportunity for the DHBs and PHOs to work collaboratively with general practice 
leads to re-establish best practice guidelines and more systematic approaches. DHBs who 
provided feedback on the draft of this document, have emphasised the need for better 
communication between the SBIP and general practice teams. Expanding ownership of the 




The initial focus for the Programme was on reducing inequalities. Ethnic inequalities in cancer 
rates result from multiple influences, including differences in: 
• underlying determinants of health 
• exposure to risk and protective factors 
• access to screening 
• access to timely, high-quality treatment.5 
 
Māori and Pacific peoples are at increased risk of developing and dying from cervical cancer 
compared with the New Zealand European population. Since the start of the Programme, 
coverage rates for Māori and Pacific have been higher than those for New Zealand European and 
other ethnicities and have reached the dose three coverage target of 60 percent. These rates are 
positive but need to be increased or at least maintained to reduce the burden of disease for these 
groups and to increase herd immunity. 
 
Immunisation providers need to re-engage with communities with low coverage, to understand 
their concerns and provide assurances about the vaccine. One strategy that has worked 
effectively in the childhood immunisation programme is the use of community immunisation 
champions who are willing to front local campaigns. 
 
There is an opportunity to liaise with Whānau Ora providers, the Māori Women’s Welfare 
League and the Pacific Allied (Women’s) Council with a view to increasing coverage in 
communities with low immunisation rates. 
 
5 Cormack D, Purdie G, Robson B. 2007. Cancer. In: Robson B, Harris R. (eds). Hauora: Māori Standards of 
Health IV: A study of the years 2000–2005. Wellington: Te Rōpū Rangahau Hauora a Eru Pōmare. 





The Programme may benefit from integration with other childhood immunisations on the 
Schedule. Possible options for improving integration include: 
• positioning the Programme in the context of the whole Schedule, as part of an ‘immunisation 
across the lifespan’ approach 
• offering the Programme at Year 7, to align with tetanus, diphtheria and acellular pertussis 
(Tdap) immunisation offered at age 11 
• establishing and maintaining closer working relationships between Programme providers 
(SBIP), general practice teams, public health, Māori and Pacific immunisation leads and local 
cervical screening programmes. 
 
Sustainability 
Changing the number of doses in the Programme from three to two would be more cost effective 
and could help increase coverage across New Zealand. In April 2014, the WHO Strategic 
Advisory Group of Experts on Immunisation recommended a two-dose schedule for girls if 
vaccination is initiated before 15 years of age. The two doses could be delivered either in Year 7, 
with a six-month gap between the doses, or in Years 7 and 8; the first could be delivered 
alongside the Tdap vaccine. 
 
In addition to savings in the cost of vaccine, there may be significant savings to DHBs by 
reducing the number of school visits. 
 
Note: any changes to the funding and eligibility criteria for vaccines on the Schedule must be 
approved through PHARMAC’s assessment, prioritisation and approval processes. 
 
DHBs who provided feedback are generally supportive of a two-dose programme. 
 
Innovation 
This section presents some ideas and questions about potential innovations in the Programme 
for further consideration. 
 
One possible innovative option would be to upgrade our National Immunisation Register (NIR) 
to provide accurate monitoring to measure effectively against the HPV target. DHBs are local 
experts and know how to get the best out of their communities, health partners and IT tools. 
 
There is potential for including boys in the Programme, as they are in Australia. Including boys 
in the Programme would de-stigmatise/normalise the vaccine as part of the routine childhood 
immunisation programme.  
 
At current costs, adding boys to the Programme will not significantly increase the coverage, but 
rather increase the Programme’s costs. In order for vaccination of school-aged boys to become 
cost-effective in New Zealand, the vaccine would need to be supplied at very low prices and 
administration costs would need to be minimised. 
 
There are opportunities for better engagement within the education sector, with a view to: 
• dispelling negative myths about the safety of the vaccine 
• ensuring providers have the knowledge and resources to understand parental concerns and 
reassure them about the safety and effectiveness of the vaccine (IMAC are currently looking 
into implementing an online learning module for the Programme) 
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 • stressing the importance of vaccinating young people because they develop a stronger 
immune response from the vaccine compared with older people 
• including education around immunisation as part of the school health curriculum. 
 
Increasing HPV coverage: an action plan 
In 2012, the Ministry developed a four-point action plan to assist with achieving the 
immunisation health targets. 
 
In light of the WHO objectives and ideas arising from consultation with DHBs, the Ministry has 
expanded and modified its four-point action plan used for the ‘Under 5s’ programme to increase 
HPV immunisation coverage. The action plan’s underlying principles are: 
• trusting relationships with parents 
• more functional relationships between SBIP and general 
practice teams 
• better quality processes, based on the Plan, Do, Check, Act  
cycle 
• recognising the role of the community. 
 
The four-point action plan uses ‘Plan, Engage, Promote and 
Monitor’ to activate change. Its implementation within the SBIP 
will support a coordinated approach between school delivery and general practice to identify 
girls who have not been vaccinated by age 16 years. There is general support to use this plan to 
achieve the new HPV target of 75 percent coverage of girls fully immunised at 12 years old by 31 
December 2017. 
 
The Programme is underpinned by effective monitoring by the Programme and NIR 
administrators. Better liaison between SBIP, general practice teams and a network of 
immunisation coordinators is important to improve the Programme’s success. 
 
The key actions will result in increased coverage, more timely HPV immunisations, more 
transparent and consistent delivery of immunisation services, better integration of services and 
better engagement between health professionals. 
 
Table 2 sets out the principles of the plan alongside associated activities and explanations in 
more detail. In addition, it sets out the relevant WHO GVAP objectives that apply to each 
principle. 
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1, 2, 3, 4 
and 5 
All DHBs plan to offer an HPV SBIP for girls in either school Year 7 or 8 by 1 February 
2017. 
School-based nurses and PHO staff collaborate to share methods to better engage with 
PHOs/general practice teams to work towards systematically delivering HPV vaccines in 
general practice to those girls aged 14 who are not fully vaccinated. 
General practice teams work with nurse leads to develop a follow-up process and provide 
catch-up for unimmunised or incompletely immunised girls, for example an annual recall 
was undertaken by GPs in November/December of their 14-year-old girls not fully protected 
against HPV. 
DHBs set yearly incremental milestone targets (eg, 2015 – 65%; 2016 – 70% and 2017 – 
75%) for all ethnicities. 






2, 4 and 5 
DHBs encourage local health professionals and community leaders to become 
immunisation champions. The local cervical screening units may have champions that are 
keen to support the Programme. 
School-based nurse leads notify children’s nominated GPs when parents or legal guardians 
indicate they wish their child to be vaccinated in general practice. When GPs receive this 
notification, the practice team pre-calls these girls at 12 years. 
School-based nurse leads engage with general practice teams to develop systems to recall 
all unvaccinated girls in their 14th year who have not received all doses of the HPV vaccine. 
General practice teams use practice systems to engage and enable opportunistic 





1, 2 and 4 
DHBs, in conjunction with their immunisation steering group leads, create specifically 
tailored promotional plans for particular local population groups. Key messages align across 
different promotional plans, including the cervical screening programme. 
Promote immunisation through school newsletters, primary care, NSUs (eg, providers 
discuss with family members presenting for cervical smears or primary HPV screening) and 
youth services. 
DHBs and PHOs promote immunisation through local media and parent groups via good 
news stories. Communications feature targeted messages, individual stories and shared 
personal experiences. 
DHBs provide pro-immunisation resources to schools and locations relevant to the target 
population (eg, recreation centres, libraries, pharmacies). 
DHBs, with support from IMAC, rebut anti-immunisation information where necessary, using 
pre-prepared statements making key points. 
DHBs support GPs and nurses with good resources and training, so that they can inform 






2, 3, 4 
and 5  
Nurse leads and general practice teams work together to address parents’ and girls’ 
concerns and identify access barriers for girls who do not respond within three months of a 
recall. 
The Ministry develops a 14-year milestone report and shares DHB coverage information 
with steering groups (from 2017 identifiable individual practice, PHO and DHB information 
will be included in the reports). 
The Ministry measures and reports to the WHO on coverage for girls aged 15 years. 
The Ministry reports on coverage by ethnicity (and from 2017, by socioeconomic status). 
The Ministry, DHBs and PHOs work together to address NIR/patient management system 
(PMS) interface issues before 2016/17. 
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 Timelines 
Table 3 sets out key events in the process of consultation on, and activities towards, achieving 
increased coverage. 
 
Table 3: Timeline for achieving increased coverage in the Programme 
Actions How Who When Support 
2015 12-year-old HPV immunisation 
coverage target increases to 65% 





teleconferences General practice teams notified by SBIP of 12-year-old girls who have 
declined HPV vaccination at 





General practice teams recall all 






2016 12-year-old HPV immunisation 
coverage target increases to 65% 





teleconferences General practice teams notified by SBIP of 12-year-old girls who have 
declined HPV vaccination at 





General practice teams recall all 






Be prepared for a likely introduction of a two-dose schedule change 
2017 12-year-old HPV immunisation 
coverage target increases to 75% 





teleconferences General practice teams notified by SBIP of 12-year-old girls who have 
declined HPV vaccination at 





General practice teams recall all 






DHBs offer HPV immunisation 
through the SBIP for girls in Year 7 
or 8 
DHBs By 1 February 
2017 (planned) 
Be prepared for a likely introduction of a two-dose schedule change 
 




Appendix A: WHO GVAP objectives, adapted for New Zealand 
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 Appendix B: 2014 HPV coverage for 2001 birth cohort 
(1 January 2014–30 June 2015) 
HPV coverage report – June 2015 Girls turning 12 years old in 2014 [Birth Cohort: 2001] 
Report run date: 07 July 2015 Period covered: 1 January 2010 to 30 June 2015 
The information contained in this report has been derived from the National Immunisation Register database. While the Ministry of Health has taken 
all reasonable steps to ensure that the information contained within the report is accurate and complete, it accepts no liability or responsibility for the 
manner in which the information is subsequently used or relied on. 
DHB Vaccination Number of HPV doses given (numerator) Estimated eligible population* (denominator) Immunisation coverage 
Maori Pacific Asian Other** All Maori Pacific Asian Other** All Maori Pacific Asian Other** All 
Auckland HPV-1 Quadrivalent 211 411 462 725 1809 270 450 630 860 2210 78% 91% 73% 84% 82% 
HPV-2 Quadrivalent 214 414 462 711 1801      79% 92% 73% 83% 81% 
HPV-3 Quadrivalent 203 401 444 689 1737      75% 89% 70% 80% 79% 
Bay of Plenty HPV-1 Quadrivalent 434 20 36 431 921 570 30 30 810 1440 76% 67% 120% 53% 64% 
HPV-2 Quadrivalent 430 20 37 416 903      75% 67% 123% 51% 63% 
HPV-3 Quadrivalent 394 17 31 389 831      69% 57% 103% 48% 58% 
Canterbury HPV-1 Quadrivalent 188 53 116 1240 1597 420 110 190 2290 3010 45% 48% 61% 54% 53% 
HPV-2 Quadrivalent 170 47 110 1140 1467      40% 43% 58% 50% 49% 
HPV-3 Quadrivalent 118 29 88 921 1156      28% 26% 46% 40% 38% 
Capital & Coast HPV-1 Quadrivalent 233 157 119 709 1218 330 220 170 990 1700 71% 71% 70% 72% 72% 
HPV-2 Quadrivalent 227 151 118 693 1189      69% 69% 69% 70% 70% 
HPV-3 Quadrivalent 217 150 119 672 1158      66% 68% 70% 68% 68% 
Counties 
Manukau 
HPV-1 Quadrivalent 668 972 433 633 2706 910 1190 690 1140 3930 73% 82% 63% 56% 69% 
HPV-2 Quadrivalent 650 955 448 648 2701      71% 80% 65% 57% 69% 
HPV-3 Quadrivalent 550 867 422 594 2433      60% 73% 61% 52% 62% 
Hawke’s Bay HPV-1 Quadrivalent 339 49 21 336 745 430 60 10 600 1100 79% 82% 210% 56% 68% 
HPV-2 Quadrivalent 329 48 21 322 720      77% 80% 210% 54% 65% 
HPV-3 Quadrivalent 315 48 19 305 687      73% 80% 190% 51% 62% 
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DHB Vaccination Number of HPV doses given (numerator) Estimated eligible population* (denominator) Immunisation coverage 
Maori Pacific Asian Other** All Maori Pacific Asian Other** All Maori Pacific Asian Other** All 
Hutt Valley HPV-1 Quadrivalent 216 81 74 351 722 270 120 90 520 1010 80% 68% 82% 68% 71% 
HPV-2 Quadrivalent 210 80 69 330 689      78% 67% 77% 63% 68% 
HPV-3 Quadrivalent 203 76 73 334 686      75% 63% 81% 64% 68% 
Lakes HPV-1 Quadrivalent 265 15 16 176 472 370 20 20 320 730 72% 75% 80% 55% 65% 
HPV-2 Quadrivalent 261 15 16 173 465      71% 75% 80% 54% 64% 
HPV-3 Quadrivalent 250 15 16 172 453      68% 75% 80% 54% 62% 
MidCentral HPV-1 Quadrivalent 246 32 41 410 729 340 40 50 700 1130 72% 80% 82% 59% 65% 
HPV-2 Quadrivalent 238 32 43 398 711      70% 80% 86% 57% 63% 
HPV-3 Quadrivalent 226 32 42 377 677      66% 80% 84% 54% 60% 
Nelson 
Marlborough 
HPV-1 Quadrivalent 96 15 17 392 520 120 15 20 710 850 80% 100% 85% 55% 61% 
HPV-2 Quadrivalent 87 15 16 384 502      73% 100% 80% 54% 59% 
HPV-3 Quadrivalent 84 15 16 359 474      70% 100% 80% 51% 56% 
Northland HPV-1 Quadrivalent 398 23 14 274 709 530 30 30 580 1170 75% 77% 47% 47% 61% 
HPV-2 Quadrivalent 383 23 14 262 682      72% 77% 47% 45% 58% 
HPV-3 Quadrivalent 361 22 12 253 648      68% 73% 40% 44% 55% 
South 
Canterbury 
HPV-1 Quadrivalent 24 4 8 150 186 40 5 0 270 320 60% 80% -% 56% 58% 
HPV-2 Quadrivalent 24 4 8 145 181      60% 80% -% 54% 57% 
HPV-3 Quadrivalent 23 3 8 140 174      58% 60% -% 52% 54% 
Southern HPV-1 Quadrivalent 179 41 44 947 1211 260 35 20 1330 1660 69% 117% 220% 71% 73% 
HPV-2 Quadrivalent 176 42 42 933 1193      68% 120% 210% 70% 72% 
HPV-3 Quadrivalent 169 39 42 898 1148      65% 111% 210% 68% 69% 
Tairawhiti HPV-1 Quadrivalent 174 8 2 67 251 220 10 5 140 370 79% 80% 40% 48% 68% 
HPV-2 Quadrivalent 173 8 2 64 247      79% 80% 40% 46% 67% 
HPV-3 Quadrivalent 164 6 2 62 234      75% 60% 40% 44% 63% 
Taranaki HPV-1 Quadrivalent 134 11 14 356 515 190 10 20 480 690 71% 110% 70% 74% 75% 
HPV-2 Quadrivalent 131 11 15 348 505      69% 110% 75% 73% 73% 
HPV-3 Quadrivalent 118 11 14 329 472      62% 110% 70% 69% 68% 
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 DHB Vaccination Number of HPV doses given (numerator) Estimated eligible population* (denominator) Immunisation coverage 
Maori Pacific Asian Other** All Maori Pacific Asian Other** All Maori Pacific Asian Other** All 
Waikato HPV-1 Quadrivalent 549 73 100 880 1602 790 90 140 1470 2490 69% 81% 71% 60% 64% 
HPV-2 Quadrivalent 539 71 99 866 1575      68% 79% 71% 59% 63% 
HPV-3 Quadrivalent 505 67 93 833 1498      64% 74% 66% 57% 60% 
Wairarapa HPV-1 Quadrivalent 51 2 5 123 181 60 5 10 150 220 85% 40% 50% 82% 82% 
HPV-2 Quadrivalent 48 2 4 124 178      80% 40% 40% 83% 81% 
HPV-3 Quadrivalent 46 2 2 114 164      77% 40% 20% 76% 75% 
Waitemata HPV-1 Quadrivalent 339 279 398 1142 2158 530 380 660 2020 3580 64% 73% 60% 57% 60% 
HPV-2 Quadrivalent 329 271 389 1124 2113      62% 71% 59% 56% 59% 
HPV-3 Quadrivalent 301 255 382 1071 2009      57% 67% 58% 53% 56% 
West Coast HPV-1 Quadrivalent 11 0 4 100 115 40 5 5 160 210 28% 0% 80% 63% 55% 
HPV-2 Quadrivalent 11 0 4 99 114      28% 0% 80% 62% 54% 
HPV-3 Quadrivalent 11 0 3 97 111      28% 0% 60% 61% 53% 
Whanganui HPV-1 Quadrivalent 128 10 8 167 313 170 5 10 240 420 75% 200% 80% 70% 75% 
HPV-2 Quadrivalent 120 10 8 166 304      71% 200% 80% 69% 72% 
HPV-3 Quadrivalent 110 9 8 154 281      65% 180% 80% 64% 67% 
Total HPV-1 Quadrivalent 4883 2256 1932 9609 18,680 6860 2830 2800 15,780 28,240 71% 80% 69% 61% 66% 
HPV-2 Quadrivalent 4750 2219 1925 9346 18,240      69% 78% 69% 59% 65% 
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